These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 35295067)
1. Propranolol use in patients with cirrhosis and refractory ascites: A nationwide study. Chen YC; Li YD; Lu CM; Huang WC; Kao SS; Chen WC Saudi J Gastroenterol; 2022; 28(2):108-114. PubMed ID: 35295067 [TBL] [Abstract][Full Text] [Related]
2. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Sersté T; Melot C; Francoz C; Durand F; Rautou PE; Valla D; Moreau R; Lebrec D Hepatology; 2010 Sep; 52(3):1017-22. PubMed ID: 20583214 [TBL] [Abstract][Full Text] [Related]
3. Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites. Onali S; Kalafateli M; Majumdar A; Westbrook R; O'Beirne J; Leandro G; Patch D; Tsochatzis EA Liver Int; 2017 Sep; 37(9):1334-1344. PubMed ID: 28296047 [TBL] [Abstract][Full Text] [Related]
4. Effect of propranolol on survival in patients with decompensated cirrhosis: a nationwide study based Danish patient registers. Bang UC; Benfield T; Hyldstrup L; Jensen JE; Bendtsen F Liver Int; 2016 Sep; 36(9):1304-12. PubMed ID: 26992041 [TBL] [Abstract][Full Text] [Related]
5. Optimal resting heart rate and ascites-related death in patients with cirrhosis and ascites using nonselective beta-blockers (ORCA). Mingpun W; Sobhonslidsuk A; Chumnumwat S Clin Transl Sci; 2024 Jan; 17(1):e13681. PubMed ID: 37950532 [TBL] [Abstract][Full Text] [Related]
7. Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis. Liu TL; Trogdon J; Weinberger M; Fried B; Barritt AS Dig Dis Sci; 2016 Nov; 61(11):3335-3345. PubMed ID: 27480088 [TBL] [Abstract][Full Text] [Related]
8. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Villanueva C; Albillos A; Genescà J; Garcia-Pagan JC; Calleja JL; Aracil C; Bañares R; Morillas RM; Poca M; Peñas B; Augustin S; Abraldes JG; Alvarado E; Torres F; Bosch J Lancet; 2019 Apr; 393(10181):1597-1608. PubMed ID: 30910320 [TBL] [Abstract][Full Text] [Related]
9. The Effect of the First Spontaneous Bacterial Peritonitis Event on the Mortality of Cirrhotic Patients with Ascites: A Nationwide Population-Based Study in Taiwan. Hung TH; Tsai CC; Hsieh YH; Tsai CC; Tseng CW; Tseng KC Gut Liver; 2016 Sep; 10(5):803-7. PubMed ID: 27563023 [TBL] [Abstract][Full Text] [Related]
10. Nonselective β-Blockers and Survival in Patients With Cirrhosis and Ascites: A Systematic Review and Meta-analysis. Chirapongsathorn S; Valentin N; Alahdab F; Krittanawong C; Erwin PJ; Murad MH; Kamath PS Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1096-1104.e9. PubMed ID: 26829026 [TBL] [Abstract][Full Text] [Related]
11. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Shukla R; Kramer J; Cao Y; Ying J; Tansel A; Walder A; Advani S; El-Serag HB; Kanwal F Am J Gastroenterol; 2016 Dec; 111(12):1778-1787. PubMed ID: 27670600 [TBL] [Abstract][Full Text] [Related]
12. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Hernández-Gea V; Aracil C; Colomo A; Garupera I; Poca M; Torras X; Miñana J; Guarner C; Villanueva C Am J Gastroenterol; 2012 Mar; 107(3):418-27. PubMed ID: 22334252 [TBL] [Abstract][Full Text] [Related]
13. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. Sinha R; Lockman KA; Mallawaarachchi N; Robertson M; Plevris JN; Hayes PC J Hepatol; 2017 Jul; 67(1):40-46. PubMed ID: 28213164 [TBL] [Abstract][Full Text] [Related]
14. Effects of beta-blockers on survival for patients with cirrhosis and refractory ascites. Lo GH Hepatology; 2011 Mar; 53(3):1068-9. PubMed ID: 21374686 [No Abstract] [Full Text] [Related]
15. Is this really the end of beta-blockers in patients with cirrhosis and refractory ascites? Thevenot T; Cervoni JP; Monnet E; Sheppard F; Martino VD Hepatology; 2011 Feb; 53(2):715-6. PubMed ID: 20814893 [No Abstract] [Full Text] [Related]
16. Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study. Lv XY; Ding HG; Zheng JF; Fan CL; Li L World J Gastroenterol; 2020 Jan; 26(2):199-218. PubMed ID: 31988585 [TBL] [Abstract][Full Text] [Related]
17. The effect of propranolol on the prognosis of hepatocellular carcinoma: A nationwide population-based study. Chang PY; Chung CH; Chang WC; Lin CS; Lin HH; Dai MS; Ho CL; Chien WC PLoS One; 2019; 14(5):e0216828. PubMed ID: 31125347 [TBL] [Abstract][Full Text] [Related]
18. Refractory Hepatic Hydrothorax Is an Independent Predictor of Mortality When Compared to Refractory Ascites. Osman KT; Abdelfattah AM; Mahmood SK; Elkhabiry L; Gordon FD; Qamar AA Dig Dis Sci; 2022 Oct; 67(10):4929-4938. PubMed ID: 35534742 [TBL] [Abstract][Full Text] [Related]
19. Nonselective Beta-Blockers Do Not Affect Survival in Cirrhotic Patients with Ascites. Facciorusso A; Roy S; Livadas S; Fevrier-Paul A; Wekesa C; Kilic ID; Chaurasia AK; Sadeq M; Muscatiello N Dig Dis Sci; 2018 Jul; 63(7):1737-1746. PubMed ID: 29725793 [TBL] [Abstract][Full Text] [Related]
20. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Kimer N; Feineis M; Møller S; Bendtsen F Scand J Gastroenterol; 2015 Feb; 50(2):129-37. PubMed ID: 25113796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]